argenx (NASDAQ: ARGX) has agreed to acquire Forte Biosciences (NASDAQ: FBRX) for $77 per share in an all-cash transaction valued at nearly $2.2 billion. The deal adds FB102, an anti-CD122 antibody with clinical proof-of-concept in celiac disease and vitiligo, strengthening argenx’s immunology pipeline while introducing the development and integration risks associated with an early-stage clinical asset.
Key Highlights
- argenx (NASDAQ: ARGX) will acquire Forte Biosciences (NASDAQ: FBRX) for $77 per share in cash.
- The transaction values Forte Biosciences (NASDAQ: FBRX) at nearly $2.2 billion on an equity basis.
- FB102 will become part of the argenx (NASDAQ: ARGX) immunology pipeline.
- FB102 has demonstrated clinical proof-of-concept in celiac disease and non-segmental vitiligo.
- The acquisition broadens argenx’s (NASDAQ: ARGX) exposure to autoimmune indications beyond its existing programmes.
Forte Biosciences Acquisition Expands argenx Immunology Strategy
The definitive merger agreement gives argenx (NASDAQ: ARGX) control of Forte Biosciences’ (NASDAQ: FBRX) principal clinical asset, FB102. The all-cash structure provides a defined consideration for Forte Biosciences (NASDAQ: FBRX) shareholders while allowing argenx (NASDAQ: ARGX) to consolidate the programme without issuing equity as transaction consideration.
The nearly $2.2 billion valuation reflects the strategic importance assigned to FB102 and its potential applicability across multiple immune-mediated diseases. The acquisition is consistent with argenx’s (NASDAQ: ARGX) strategy of identifying differentiated immunology mechanisms that could address patient populations with limited treatment options.
FB102 Adds a Differentiated Anti-CD122 Mechanism
FB102 is an anti-CD122 monoclonal antibody designed to target a component of the interleukin-2 and interleukin-15 receptor pathways. These pathways regulate natural killer cells and certain T-cell populations involved in autoimmune responses. Targeting CD122 may therefore offer a distinct mechanism for modifying immune activity across several conditions.
Forte Biosciences (NASDAQ: FBRX) has reported clinical proof-of-concept for FB102 in celiac disease and vitiligo. These findings provide initial human evidence supporting the biological rationale, although subsequent trials will still need to establish the therapy’s efficacy, safety, dosing profile and durability in larger patient populations.
Pipeline Opportunity Accompanied by Clinical Risk
For argenx (NASDAQ: ARGX), the transaction adds a potentially multi-indication asset and expands the company’s development pipeline in autoimmune disease. The broader opportunity will depend on whether FB102 can demonstrate consistent results across later-stage studies and whether its mechanism offers clinically meaningful differentiation from existing and emerging treatments.
The principal risks remain clinical execution, regulatory requirements, integration costs and the capital needed to advance several indications. Clinical proof-of-concept reduces some early scientific uncertainty but does not ensure successful registration or commercial adoption. The acquisition consequently increases argenx’s (NASDAQ: ARGX) pipeline breadth while concentrating substantial transaction value in the future performance of FB102.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...